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Objective: To determine the most cost-effective approach to the management of distal ureteral 
stones in children given the potential for recurrent renal colic during a trial of passage versus 
potential stent discomfort and complications of ureteroscopy.   
Methods: We developed a decision tree to project costs and clinical outcomes associated with 
observation, medical explusive therapy (MET), and ureteroscopy for the management of an 
index patient with a 4mm distal ureteral stone. We determined which strategy would be least 
costly and offer the most pain-free days within 30 days of diagnosis.  We performed a one-way 
sensitivity analysis on the probability of successful stone passage with MET. We obtained 
probabilities from the literature and costs from the 2016 Pediatric Health Information System 
Database. 
Results: Ureteroscopy was the costliest strategy but maximized the number of pain-free days 
within 30 days of diagnosis ($5,282/29 pain-free days).  MET was less costly than ureteroscopy 
but also less effective ($615/21.8 pain-free days).  Observation cost more than MET and was 
___________________________________________________________________
This is the author's manuscript of the article published in final edited form as:
Chan, K. H., Whittam, B. M., Krambeck, A., Downs, S. M., Misseri, R., Cain, M. P., & Bennett, W. E. (2019). Cost-effectiveness 
analysis of the management of distal ureteral stones in children. Urology. https://doi.org/10.1016/j.urology.2019.02.007
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
2 
 
also less effective ($2,139/15.5 pain-free days). The one-way sensitivity analysis on the 
probability of successful stone passage with MET demonstrated that ureteroscopy always has 
the highest net monetary benefits value and is therefore the recommended strategy given a 
fixed WTP. 
Discussion: Using a rigorous decision-science approach, we found that ureteroscopy is the 
recommended strategy in children with small distal ureteral stones.  Although it cost more than 
MET, it resulted in more pain-free days in the first 30 days following diagnosis given the faster 
resolution of the stone episode.   
 
Introduction 
The incidence of nephrolithiasis is increasing in children and the economic impact is 
significant. [1, 2]  The management options for children who present with ureteral 
stones include: (1) a trial of spontaneous passage, (2) medical expulsive therapy (MET), 
(3) ureteroscopy, and (4) extracorporeal shock wave lithotripsy (SWL).  The 2016 
American Urological Association guidelines recommend a trial of spontaneous passage 
or MET for children with uncomplicated ureteral stones less than or equal to 10 mm.[3] 
Parents may elect ureteroscopy or SWL for children with proximal or mid ureteral stones 
who cannot pass their stone spontaneously.[3]  The guidelines recommend 
ureteroscopy for children with distal ureteral stone that fail a trial of observation or MET.  
SWL is not indicated for these patients due to poor penetration of shock waves in the 
pelvis and limited efficacy. In addition, there are concerns about its long-term adverse 
effects and evidence of decreasing utilization.[4, 5]   
In a recent meta-analysis, pediatric patients who received alpha-blockers as part of 
MET had 2.2 times the odds of stone passage within 6 weeks compared to those who 
did not.[6]  There is evidence, however, that physicians do not prescribe MET 
consistently in children.[7]  In one retrospective multi-institutional cohort study of 
pediatric patients with ureteral stones up to 10 mm, only 36% of them received MET.[8]  
There are potential disadvantages to observation, MET and ureteroscopy.  Patients who 
elect observation or MET may have recurrent episodes of renal colic resulting in 
repeated visits to the clinic or Emergency Department (ED).  They also may limit 
activities and/or miss school while awaiting spontaneous stone passage.  In a study of 
adults with ureteral stones, 11% visited the ED again within 30 days of stone 
diagnosis.[9]  Ureteroscopy is more costly than the other options and patients may 
experience stent-related discomfort postoperatively. 
The objective of our study was to compare the cost-effectiveness of three strategies for 
the management of ureteral stones in children: (1) observation, (2) MET, and (3) 
ureteroscopy. Our goal was to determine which strategy would be least costly and offer 
the most pain-free days within 30 days of diagnosis (i.e. most cost-effective).   
Methods 
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Model structure 
We developed a decision tree (Figure 1) to project costs and clinical outcomes 
associated with the management of uncomplicated, small, distal ureteral stones in 
children from the perspective of the healthcare system.  We defined “uncomplicated” 
patients as those with no signs of sepsis or acute renal failure, no solitary kidney, and 
no bilateral obstruction.  We compared three strategies, (1) observation, (2) MET, and 
(3) ureteroscopy.  We defined MET as a 14-day trial of stone passage with a daily 
alpha-blocker such as tamsulosin.  The model simulated costs and clinical outcomes for 
a hypothetical 10-year old female patient with a 4mm distal ureteral stone (Figure 1). 
We estimated the total number of pain-free days within the first 30 days following the 
onset of acute renal colic.   
Key assumptions 
Some of the key simplifying assumptions in this model included the following: 
(1) There were no stones in the kidney. 
(2) There was no evidence of urinary tract infection. 
(3) If the patient did not spontaneously pass the stone within 14 days of diagnosis (in 
either MET or observation branches) she would undergo ureteroscopy. 
(4) The urologist always achieved retrograde access for ureteroscopy without active or 
passive dilation.  (The model assumes that a variety of ureteroscopes are available 
including ultra-thin 4.5 Fr semi-rigid ureteroscopes).[10-12] 
(5) The urologist always placed a ureteral stent after ureteroscopy. 
(6) All patients removed the ureteral stent with a string at home. 
(7) One ureteroscopy was required for stone clearance. 
(8) All patients were stone-free within 30-days of stone diagnosis.  
Model parameterization 
Appendix 1 shows the base case values for selected model parameters.  To the extent 
possible, we used published scientific articles to derive these parameter estimates.  
Models were created using TreeAge Pro 2017 (TreeAge Software, Inc., Williamstown, 
MA).  We did not seek Institutional Review Board approval for this study because we 
used only publicly available resources for parameterizing our model. 
Probabilities 
We used specific probabilities from the pediatric and adult stone literature to define the 
likelihood of the index patient progressing to each branch in the decision tree (Appendix 
1).  We extrapolated probabilities from the adult literature when pediatric data were not 
available.  In the MET and observation branches we modeled the probability of a visit to 
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the ED within 30 days of diagnosis of the symptomatic ureteral stone.[9]  In the MET 
branch, we modeled the probability of a MET-related adverse event using data from a 
systematic review of medical expulsive therapy in children.[6]  We assumed that the 
cost of a MET-related adverse event was roughly equivalent to the cost of a visit to the 
ED.  We determined the probability of spontaneous stone passage and median time to 
passage in the MET and observation branches from a randomized controlled trial of 
tamsulosin in children with ureteral stones.[13]  We determined the probability of 
perioperative ureteroscopy-related complications based on the incidence of Satava and 
Clavien grade 3 complications from a systematic review of pediatric ureteroscopy 
studies.[14, 15] We assumed that the cost associated with a perioperative complication 
was roughly equivalent to a 23-hour hospital stay.  Given that surgery might be 
required, a) the cost of a 23-hour hospital stay alone likely represents the minimal cost 
of managing a perioperative complication and b) our assumption biases in favor of 
ureteroscopy.  We also modeled the probability of perioperative anesthetic adverse 
events requiring rapid response assistance.[16]  We assumed that patients who had a 
perioperative ureteroscopic or anesthetic-related adverse events would be admitted to 
the hospital for a 23-hour observation.  Finally, we modeled the probability of a visit to 
the ED within 30 days after the ureteroscopy based on data from a large series of adult 
patients.[17] 
Costs   
We derived costs associated with the various health states in the model primarily from 
the Pediatric Health Information System, an administrative database from approximately 
54 U.S. children’s hospitals (Appendix 2).[18]  We extracted median adjusted Ratio of 
Cost to Charges (RCC) based costs for common outpatient kidney stone procedures 
from January 1, 2016 to December 31, 2016. We determined the median cost of 
outpatient ureteroscopy with laser lithotripsy and ureteral stent placement at United 
States children’s hospitals in 2016. We excluded patients with concurrent procedures in 
order to avoid inclusion of non-stone procedures such as pyeloplasty that commonly 
involve ureteral stent placement. We assumed that costs for adverse events associated 
with MET were equivalent to one ED visit. We calculated the median cost of a visit to 
the ED for any reason at U.S. children’s hospitals in 2016, as a precise estimate of an 
ED visit for a medication side effect was difficult to ascertain.  We also included costs of 
ED visits during a trial of spontaneous passage (with or without MET) and the costs of 
ED visits post-ureteroscopy. We assumed that costs for a perioperative complication 
were roughly equivalent to a 23-hour admission to the hospital. We used Access 
Medicine to determine the cost of a 30-day supply of tamsulosin.[19] 
Outcomes assessed 
The primary outcomes assessed were the costs and clinical outcomes among children 
with symptomatic distal ureteral stones. We estimated the total number of pain-free 
days within the first 30 days following the onset of acute renal colic.  First, we 
determined the number of symptomatic stone days defined as the time from the 
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diagnosis of the symptomatic ureteral stone to the day of stone clearance (Appendix 3).  
We considered patients “stone-free” after they passed the stone spontaneously or 
removed the stent following ureteroscopy.  We subtracted the number of symptomatic 
stone days from thirty in order to determine the number of pain-free days within 30 days 
of diagnosis.    
We performed a one-way sensitivity analysis in which we varied the probability of 
successful stone passage with MET from 0 to 1.  We performed a net benefits 
calculation, combining cost, effectiveness and willingness-to-pay (WTP) ($50,000) into a 
single value. The strategy with the highest net benefits value is the recommended 
strategy given a fixed WTP.  If one strategy’s line is always the highest on the vertical 
benefits scale, there are no CE thresholds in that case for the given variable range and 
WTP.   
Figure 1 depicts the initial branches of the decision tree including the probability of a 
repeated ED visit within the first 30 days after diagnosis of the ureteral stone.  There are 
also branches modeling the probability of an adverse event related to MET and the 
probability of a perioperative complication at the time of ureteroscopy. In addition, we 
modeled the probability of a repeated ED visit following ureteroscopy. Finally, if the 
index patient failed a trial of observation or MET, she progressed to ureteroscopy in the 
model.  
Results 
Base-case results 
Under base-case assumptions, ureteroscopy was the costliest strategy but maximized 
the number of pain-free days within 30 days of diagnosis ($5,282/29 pain-free days) 
(Table 1).  MET was less costly than ureteroscopy but also less effective ($615/21.8 
pain-free days).  Observation cost more than MET and was also less effective 
($2,139/15.5 pain-free days).  Therefore, the observation strategy is dominated by MET.  
Figure 2 depicts the cost-effective frontier which is a line connecting the two strategies, 
ureteroscopy and MET, that are not dominated.  The willingness-to-pay slope intersects 
with the favored strategy which, in this case, is ureteroscopy. 
Sensitivity analysis   
The one-way sensitivity analysis on the probability of successful stone passage with 
MET demonstrated that ureteroscopy always has the highest net monetary benefits 
value (i.e. the lines for MET and ureteroscopy do not intersect) and is therefore the 
recommended strategy given a fixed WTP. 
Discussion  
Using a rigorous decision-science approach, we found that ureteroscopy is the 
recommended strategy in children with small distal ureteral stones.  Although it cost 
more than MET, it resulted in more pain-free days in the first 30 days following 
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diagnosis given the faster resolution of the stone episode.  We also noted that MET is 
always more effective and less costly than observation and thus should be utilized in all 
eligible children.  URS maximizes the number of pain-free days within the first 30 days 
after diagnosis and costs approximately $4600 more than MET and approximately 
$1500 more than observation.   The increased probability of spontaneous passage and 
decreased time to stone passage likely explains the decreased cost of MET compared 
to observation since patients have fewer opportunities for ED visits.  The cost of a 30-
day supply is nominal and MET-related adverse events are rare.  
Although ureteroscopy was the preferred strategy in our study for managing 
small distal ureteral stones in children, it has several disadvantages including stent 
discomfort, perioperative complications, and increased cost.  Tamsulosin is still a 
reasonable option for pediatric patients with small distal ureteral stones who wish to 
avoid the risks of surgery and the potential sequelae of ureteral stent placement.  
Despite evidence of the safety and efficacy of tamsulosin, it is underutilized for children 
with ureteral stones.[7]  A recent study using commercial claims data found that only 
15% of children evaluated for ureteral stones in the ED filled a prescription for MET 
within one week of their visit.[7]  Joshi and colleagues estimated that approximately 
80% of adults experience stent discomfort that has a negative impact on quality of 
life.[20] Therefore, identification of patients most likely to benefit from MET could help 
avoid some of the adverse effects associated with ureteroscopy and ureteral stenting.   
Meta-analyses of numerous randomized controlled trials of tamsulosin for adults 
with ureteral stones confirmed that patients treated with tamsulosin have higher stone 
expulsion rates and lower analgesic requirements.[21-23]  Several recent high quality, 
large randomized controlled trials, however, have questioned the clinical effectiveness 
of tamsulosin for MET.[24, 25]  The Spontaneous Urinary Stone Passage by Drugs 
(SUSPEND) trial found that neither tamsulosin nor nifedipine decreased the need for 
treatment of ureteral stones to achieve stone clearance after four weeks.[25]  Another 
multi-center, phase III trial found no benefit of tamsulosin for patients with distal ureteral 
stones less than or equal to 10 mm in terms of spontaneous passage, time to stone 
passage or analgesic requirements.[24]  In a subgroup analysis of patients with larger 
distal ureteral stones, however, tamsuloin increased stone passage.[24]  Ye and 
colleagues recently published the largest multi-center, randomized, double blind trial to 
date comparing comparing tamsulosin to placebo.[26]  Patients in the tamsulosin group 
had a higher stone expulsion rate, a shorter time to expulsion and lower use of 
analgesics.[26]  Subgroup analysis identified a specific benefit for tamsulosin for the 
treatment of large distal ureteral stones (>5mm).   Furthermore, a recent meta-analysis 
of three randomized controlled trials and two retrospective cohort studies in pediatric 
patients found that MET increased the odds of stone passage by approximately two-fold 
compared to observation.[6]   
Prior cost-effectiveness studies in the adult stone literature have compared 
ureterosopy to SWL for renal calculi.[27, 28] In an instrumental variable analysis, 
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Hollingsworth and colleagues noted that expenditures were significantly lower after MET 
versus endoscopic stone removal in patients with ureteral stones.[29]  To our 
knowledge, there are no prior cost-effectiveness analyses in the adult or pediatric stone 
literature comparing observation, MET and ureteroscopy.  
The primary limitation of this study is the relative paucity of reliable data in 
children to estimate parameters in our model.  We made several assumptions about 
probability and costs which might limit the generalizability of our results to some 
populations and clinical scenarios. As such, we included data from small, pediatric 
randomized controlled trials comparing MET to observation and we extrapolated data 
from the adult literature when pediatric data were not available.  Other limitations 
include the omission of parent and patient-centered outcomes such as missed days of 
work/school and stent-related discomfort.  We also did not use utilities for the decision 
tree since there are no published utilities for pediatric stone disease.  To our knowledge, 
there are no published utilities for certain stone procedures such as ureteroscopy even 
in the adult population.  
Conclusions 
In children with small distal ureteral stones, ureteroscopy is the preferred strategy and 
medical expulsive therapy is superior to observation. Future studies are needed to 
determine parental/child preferences in the management of pediatric stone disease and 
to expand our knowledge of the costs and probabilities used to parameterize the model. 
 
Figure Legends 
Figure 1: Decision tree with initial branches 
Figure 2: Cost-effectiveness analysis of options for the management of small distal 
ureteral stones in children 
Figure 3: One-way sensitivity analysis on the probability of stone passage with medical 
expulsive therapy 
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Table 1: Cost-effectiveness of three strategies for management of small, distal ureteral 
stones in children 
 Cost Incr. 
cost 
Ave. 
effectiveness 
Incr. 
effectiveness 
Ave. cost-
effectiveness 
ICER 
*MET $615  21.8  28.2 0 
**OBS $2,139 $1,524 15.5 -6.30 138.2 -241.8 
***URS $5,282 $4,667 29.0  7.19 182.3 649.4 
*MET=medical expulsive therapy 
**OBS = observation 
**URS=ureteroscopy 
Ave.= verage 
Incr. = Incremental 
 
